In the first-in-human trial of elranatamab, patients with refractory or relapsed multiple myeloma who received the bispecific antibody against BCMA and CD3 experienced no dose-limiting toxicities during dose escalation, and the agent showed promising clinical efficacy.
- Nizar J. Bahlis
- Caitlin L. Costello
- Alexander M. Lesokhin